Resetting the Evidence Bar for New Anticancer Drug Approvals - Summary - MDSpire

Resetting the Evidence Bar for New Anticancer Drug Approvals

  • By

  • Stacie B. Dusetzina

  • Shelley A. Jazowski

  • June 9, 2026

  • 0 min

Share

Objective:

Clarify the connection between the adequacy of information and its implications for patient decision-making.

Key Findings:
  • Include source attribution for statistics.
Interpretation:

Remove unsupported conclusions about patient priorities.

Limitations:
  • Make limitations more concise.
Conclusion:

Remove unsupported recommendations about informing patients.

Original Source(s)

Resetting the Evidence Bar for New Anticancer Drug Approvals

  • by Stacie B. Dusetzina, Shelley A. Jazowski

  • June 9, 2026

Related Content

A patient with triple-negative breast cancer developed acute myocardial infarction after docetaxel chemotherapy: case report and literature review

Diagnosis and treatment of breast cancer metastasis to thyroid: a case report and literature review

Editorial: Epigenetic modulation in cancer